A monoclonal antibody cocktail developed by Regeneron reduced risk of developing symptomatic COVID-19 by 81% in household contacts living with a positive case, company said.
from Livescience.com https://ift.tt/3s5QFb2
via IFTTT
from Livescience.com https://ift.tt/3s5QFb2
via IFTTT
Comments
Post a Comment